Richard Drury U.S. materials stocks have suffered sharp losses over the past month, with the S&P 500 Materials sector index plunging roughly 7% through late March. Below is a list of the top 10 performing materials sector stocks ranked by their price performance percentage in March. The list is topped by Alto Ingredients, Inc. ( ALTO ), with a remarkable 97.81% gain and a Strong Buy Quant Rating o...
Richard Drury U.S. materials stocks have suffered sharp losses over the past month, with the S&P 500 Materials sector index plunging roughly 7% through late March. Below is a list of the top 10 performing materials sector stocks ranked by their price performance percentage in March. The list is topped by Alto Ingredients, Inc. ( ALTO ), with a remarkable 97.81% gain and a Strong Buy Quant Rating of 4.98. LSB Industries, Inc. ( LXU ) and LyondellBasell Industries N.V. ( LYB ) follow with gains of 40.28% and 39.86% respectively, both also carrying Strong Buy ratings. Rare Element Resources Ltd. ( REEMF ) and CVR Partners, LP Common Units ( UAN ) round out the top five. The list features a variety of industries within the materials sector, including specialty chemicals, commodity chemicals, fertilizers, and metals and mining. While top performers like Alto Ingredients ( ALTO ), LSB Industries ( LXU ), and LyondellBasell ( LYB ) carry Strong Buy ratings, industry giants such as Dow Inc. ( DOW ) and Celanese Corporation ( CE ) hold ratings of Hold at 3.41 and 3.15 respectively. Some entries, including Rare Element Resources ( REEMF ) and CVR Partners ( UAN ), are not currently covered by the Quant system. Here is the list: Alto Ingredients, Inc. ( ALTO ), 1 month performance percentage: 97.81% LSB Industries, Inc. ( LXU ), 1 month performance percentage: 40.28% LyondellBasell Industries N.V. ( LYB ), 1 month performance percentage: 39.86% Rare Element Resources Ltd. ( REEMF ), 1 month performance percentage: 37.70% CVR Partners, LP Common Units ( UAN ), 1 month performance percentage: 37.61% Alpha Metallurgical Resources, Inc. ( AMR ), 1 month performance percentage: 37.26% CF Industries Holdings, Inc. ( CF ), 1 month performance percentage: 37.08% AdvanSix Inc. ( ASIX ), 1 month performance percentage: 34.94% Dow Inc. ( DOW ), 1 month performance percentage: 32.83% Celanese Corporation ( CE ), 1 month performance percentage: 26.97% Materials ETFs : ( XLB ), ( VAW ), ( I...
Welcome back to Bloomberg’s Auto Monitor , a weekly roundup of stories on the automotive industry from reporters around the world. Sign up now if you’re not already on the list. BYD’s meteoric rise looks to be slowing . The Chinese electric-vehicle powerhouse just reported lower-than-expected fourth-quarter earnings, and customers are complaining about its God’s Eye driver-assistance product. We h...
Welcome back to Bloomberg’s Auto Monitor , a weekly roundup of stories on the automotive industry from reporters around the world. Sign up now if you’re not already on the list. BYD’s meteoric rise looks to be slowing . The Chinese electric-vehicle powerhouse just reported lower-than-expected fourth-quarter earnings, and customers are complaining about its God’s Eye driver-assistance product. We have stories detailing Chinese automakers’ performance in Europe in February and how it feels to drive Aston Martin’s $1 million Valhalla . All this and more, below. Market Snapshot BYD Co Ltd $105.80 -0.7% Toyota Motor Corp $3,255.00 -3.1% Tesla Inc $361.83 -2.8% Volkswagen AG $88.20 -0.5% Market data as of 09:17 AM ET. Data is subject to provider delays. BYD’s Difficult 2026 For years, BYD could do little wrong. Powered by China’s rapid shift to EVs, it enjoyed runaway sales and profit, overtaking Tesla as the biggest maker of battery-powered cars. But now it’s hitting its first roadblocks. On Friday, the maker of the Dolphin hatchback reported a steeper-than-expected decline in fourth-quarter earnings and its first annual profit drop in four years. Revenue growth was the slowest in six years, and 2026 hasn’t started any better. BYD’s global sales slumped in January and February, and the company lost the top spot in its home market to Geely. It’s not easy selling cars in China right now. Price competition remains fierce, and BYD has to spend heavily to keep up with new entrants like Huawei and Xiaomi that are offering affordable EVs decked out with the latest technology. Consumers are grappling with a protracted real estate slowdown and a reduction in purchase tax exemptions. Competition in China “has reached a fever pitch, and is undergoing a brutal ‘knockout stage,’” BYD Chairman Wang Chuanfu said in a letter to shareholders. Part of the sales slowdown may be self-inflicted. Some Chinese customers have taken to social media with complaints about God’s Eye , the driver-as...
Eikon Therapeutics, Inc. press release ( EIKN ): FY GAAP EPS of -$115.29. Eikon expects its current cash, cash equivalents, and marketable securities, which includes proceeds from its February 2026 IPO, will fund operations into the second half of 2027. More on Eikon Therapeutics, Inc. Eikon Therapeutics Launches IPO For Ambitious Oncology Pipeline Development Eikon Therapeutics prices upsized IPO...
Eikon Therapeutics, Inc. press release ( EIKN ): FY GAAP EPS of -$115.29. Eikon expects its current cash, cash equivalents, and marketable securities, which includes proceeds from its February 2026 IPO, will fund operations into the second half of 2027. More on Eikon Therapeutics, Inc. Eikon Therapeutics Launches IPO For Ambitious Oncology Pipeline Development Eikon Therapeutics prices upsized IPO of 21.18M shares at $18.00 Merck reportedly eyeing $30M stake in Eikon Therapeutics’ IPO Historical earnings data for Eikon Therapeutics, Inc. Financial information for Eikon Therapeutics, Inc.
It may be the end of March, but gaming companies are already getting ready for the summer. First up is Xbox, which just announced that it will be holding its next major showcase event on June 7th. That's a typical window for Microsoft - last year's edition took place on June 8th - and fits snugly into the timeframe of Summer Game Fest . It's an important moment for Microsoft's gaming division, whi...
It may be the end of March, but gaming companies are already getting ready for the summer. First up is Xbox, which just announced that it will be holding its next major showcase event on June 7th. That's a typical window for Microsoft - last year's edition took place on June 8th - and fits snugly into the timeframe of Summer Game Fest . It's an important moment for Microsoft's gaming division, which just saw a big upheaval in which long-time Xbox boss Phil Spencer retired with Asha Sharma taking over as CEO . The showcase will be an opportunity to show what the current state of the Xbox platform is. It will be livestreamed but also include an … Read the full story at The Verge.
Apple ( AAPL ) was in focus on Monday as investment firm Melius Research reiterated its Buy rating on the iPhone maker. “Given Apple’s free cash flow and we are about to embark on one of its most lucrative product rollouts since the big screen iPhones in 2014 - there is a case for Apple’s stock regaining some ground,” Melius analysts wrote in a note to clients. Apple shares were modestly higher in...
Apple ( AAPL ) was in focus on Monday as investment firm Melius Research reiterated its Buy rating on the iPhone maker. “Given Apple’s free cash flow and we are about to embark on one of its most lucrative product rollouts since the big screen iPhones in 2014 - there is a case for Apple’s stock regaining some ground,” Melius analysts wrote in a note to clients. Apple shares were modestly higher in premarket trading. Lately, Apple has announced the iPhone 17e and a refreshed iPad Air , a new MacBook Air, a MacBook Pro, new Studio Displays, the MacBook Neo , and an updated version of its over-the-ear headphones, the AirPods Max 2 . Apple shares were modestly higher in premarket trading but have lost some 8% year-to-date. Over the past 12 months, shares have gained 12%. More on Apple Apple's 50th Anniversary: A 'Solid Hold' For Wealth Preservation Apple Stock Price Firms Near $252 After WWDC Date Steadies Sentiment Apple Stock Price Slips At $252 As Tech Investors Pivot To Defensive Positioning Catalyst Watch: Jobs report, Nike earnings, and Apple turns 50 Apple hires ex-Google marketing exec for AI push
Apple ( AAPL ) was in focus on Monday as investment firm Melius Research reiterated its Buy rating on the iPhone maker. “Given Apple’s free cash flow and we are about to embark on one of its most lucrative product rollouts since the big screen iPhones in 2014 - there is a case for Apple’s stock regaining some ground,” Melius analysts wrote in a note to clients. Apple shares were modestly higher in...
Apple ( AAPL ) was in focus on Monday as investment firm Melius Research reiterated its Buy rating on the iPhone maker. “Given Apple’s free cash flow and we are about to embark on one of its most lucrative product rollouts since the big screen iPhones in 2014 - there is a case for Apple’s stock regaining some ground,” Melius analysts wrote in a note to clients. Apple shares were modestly higher in premarket trading. Lately, Apple has announced the iPhone 17e and a refreshed iPad Air , a new MacBook Air, a MacBook Pro, new Studio Displays, the MacBook Neo , and an updated version of its over-the-ear headphones, the AirPods Max 2 . Apple shares were modestly higher in premarket trading but have lost some 8% year-to-date. Over the past 12 months, shares have gained 12%. More on Apple Apple's 50th Anniversary: A 'Solid Hold' For Wealth Preservation Apple Stock Price Firms Near $252 After WWDC Date Steadies Sentiment Apple Stock Price Slips At $252 As Tech Investors Pivot To Defensive Positioning Catalyst Watch: Jobs report, Nike earnings, and Apple turns 50 Apple hires ex-Google marketing exec for AI push
Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit growth as expanding further becomes an increasingly challenging task.
Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit growth as expanding further becomes an increasingly challenging task.
Nicolae Popescu/iStock via Getty Images Since my article , "My Top 5 Biotech Stocks Big Pharma Could Buy Next," Kamada shares ( KMDA ) have risen 22.4%, outperforming the so-called "bellwether" for the biotech investors, the iShares Biotechnology ETF [6.5% return] ( IBB ), as well as the S&P 500 [-3.9%] ( SPY ). And to my surprise, this happened even after it announced on December 8 last year that...
Nicolae Popescu/iStock via Getty Images Since my article , "My Top 5 Biotech Stocks Big Pharma Could Buy Next," Kamada shares ( KMDA ) have risen 22.4%, outperforming the so-called "bellwether" for the biotech investors, the iShares Biotechnology ETF [6.5% return] ( IBB ), as well as the S&P 500 [-3.9%] ( SPY ). And to my surprise, this happened even after it announced on December 8 last year that it was discontinuing its Phase 3 InnovAATe study [ NCT04204252 ], because Inhaled AAT was unlikely to improve lung function measured by FEV1. On the other hand, KMDA's revenue rose 11.8% year-over-year to $44.12 million , beating my "base case" scenario by $1.6 million. And its non-GAAP EPS came below the consensus estimate, as it had in 2 of the previous 7 quarters, but this time by 2 cents . Source: graph was made by Author based on Seeking Alpha Now, I will start to answer whether, according to my "ALLKA 4D Rating" model, Kamada still has an appealing risk/reward ratio or whether it's time to downgrade its rating from Buy to Hold or even to Sell. Kamada is capturing the plasma market So, I will continue with Kamada's Proprietary Products segment, which is quite rich and includes 8 medications . Source: graph was made by Author based on the 20-F of Kamada Because it's one of the leaders in the plasma-derived medicinal products market, the revenue of this unit grew 21.7% year-on-year to $38.2 million in Q4. Source: graph was made by Author based on the financial reports of Kamada And to be more specific, in my view, the two key drugs are KamRAB/KedRAB and Glassia. The first one is HRIG, approved by the FDA , among other regulatory authorities, for transient post-exposure prophylaxis. By the way, KedRab's mechanism of action is quite simple. After injection at the site of the bite, neutralizing antibodies bind to the rabies virus and, as a result, prevent progressive encephalomyelitis . And according to PubMed, if this neurological condition is left untreated, it causes ov...
(RTTNews) - Velo3D Inc. (VELO), a metal 3D printing technology company, on Monday said it has been awarded a $9.8 million multi-year contract from the Department of War supporting the Defense Logistics Agency.
(RTTNews) - Velo3D Inc. (VELO), a metal 3D printing technology company, on Monday said it has been awarded a $9.8 million multi-year contract from the Department of War supporting the Defense Logistics Agency.
UBS AG is telling investors to seek protection against potential losses in emerging-market credit as the fallout from the escalating war in Iran threatens developing economies. The Swiss bank recommends positioning in an emerging-market index of credit-default swaps, known as the Markit CDX-EM index, alongside selective bearish bets in developing-nation currencies. While the conflict has roiled EM...
UBS AG is telling investors to seek protection against potential losses in emerging-market credit as the fallout from the escalating war in Iran threatens developing economies. The Swiss bank recommends positioning in an emerging-market index of credit-default swaps, known as the Markit CDX-EM index, alongside selective bearish bets in developing-nation currencies. While the conflict has roiled EM stocks and local yields as oil surged, credit spreads have shown a more muted reaction, leaving them vulnerable to further swings. “We see CDX-EM and selected shorts in EMFX as attractive hedges to further possible energy disruption in coming weeks,” strategists including Manik Narain wrote in a note on Monday. Last week, Morgan Stanley similarly advised hedging via the same CDS index, targeting a spread of 240 basis points with a stop at 180 basis points. The current spread is hovering around 197 basis points. “In the absence of a sustained de-escalation in the Middle East, we expect spreads to widen, reflecting increasingly persistent negative economic impacts,” strategists including Simon Waever wrote in a note dated March 23. Spreads have been little changed since the recommendation. The new CDS index composition is more skewed toward high-yield names following the addition of several junk-rated issuers, with such debt now accounting for 55% of the index, up from 47%, Waever wrote. Regionally, the bank expects Latin America to continue outperforming, citing attractive risk-reward opportunities in credits ranging from Ecuador to Argentina.
As the healthcare industry scrambles to integrate artificial intelligence, Eli Lilly is signaling it was already ahead of the curve. InSilico, a self-professed “AI-driven biotech company,” unveiled a deal with the drugmaker Sunday that could be valued at up to $2.75 billion. Under the terms of the arrangement, Lilly will receive exclusive worldwide rights to manufacture and sell oral treatments di...
As the healthcare industry scrambles to integrate artificial intelligence, Eli Lilly is signaling it was already ahead of the curve. InSilico, a self-professed “AI-driven biotech company,” unveiled a deal with the drugmaker Sunday that could be valued at up to $2.75 billion. Under the terms of the arrangement, Lilly will receive exclusive worldwide rights to manufacture and sell oral treatments discovered using InSilico’s Pharma.AI model.
Monty Rakusen/DigitalVision via Getty Images This is a classic case of a narrative outrunning the business. Amprius Technologies, Inc. ( AMPX ) is a ~$2.2B hardware company with ~11% gross margins, deeply negative operating margins, and a history of cash burn—yet it trades at ~30x trailing sales after a 10x move in under a year—a move that reflects not just improving fundamentals but significant n...
Monty Rakusen/DigitalVision via Getty Images This is a classic case of a narrative outrunning the business. Amprius Technologies, Inc. ( AMPX ) is a ~$2.2B hardware company with ~11% gross margins, deeply negative operating margins, and a history of cash burn—yet it trades at ~30x trailing sales after a 10x move in under a year—a move that reflects not just improving fundamentals but significant narrative expansion. Moves like this typically resolve with violent mean reversion, not stability. The stock is being valued like a differentiated, defensible winner in next-generation batteries—almost like a high-margin platform. It isn’t. This is a capital-intensive manufacturing business where mistakes show up in cash burn, not PowerPoint. Long-term outcomes are determined by cost curves, yield, and supply chain execution. Investors are not being paid for execution risk—they are underwriting perfection. That is how you lose money in hardware. The fundamentals don’t support the valuation. 2025 revenue was $73M (+200% YoY), with gross margins improving to 11.3%. Management is guiding to ~$125M in 2026 revenue alongside positive adjusted EBITDA of at least $4 million, but the business still depends heavily on third-party manufacturing and carries a $120M shelf registration. Even if guidance is met, the valuation leaves no room for delays, dilution, or margin pressure—standard operating reality in hardware, not downside scenarios. The manufacturing model is a key, underappreciated risk. Without full control of production at scale, it is harder to defend margins, resolve yield issues quickly, or drive unit cost reductions. That matters when competing against players with vastly greater capital and manufacturing leverage. The competitive landscape is far more serious than the market is pricing. Silicon-anode batteries are not a greenfield opportunity—they are a crowded, capital-rich battleground. Well-funded players like Sila Nanotechnologies and Group14 are scaling automotive-...